/PRNewswire/ ABclonal Technology, a rapidly growing life science research and diagnostic reagents manufacturer, today announced it has joined the Industry.
Published: Mar 05, 2021 By Mark Terry
Boston-based ABclonal Biotechnology
acquiredcontract research organization (CRO) Yurogen Biosystems, headquartered in nearby Worcester, Massachusetts. Yurogen focuses on producing antibodies and antibody-based products for its clients. Its technology platform is a monoclonal antibody discovery program using single-B-cell-based SMab. This technology platform allows for high-throughput development of high-affinity, high-specificity monoclonal antibodies. No financial details were disclosed.
Late in February, ABclonal, which calls itself a global life sciences tools and services provider,
completed a Series C financing round worth $92.9 million. It was led by Sequoia Capital China and healthcare-focused investors LYFE Capital. New and existing shareholders included Sigma Square Capital, Kinghall Ventures and Lucion Capital.
ABclonal Biotechnology Acquires Yurogen Biosystems to Better Serve Diagnostic and Pharmaceutical Researchers Worldwide
News provided by
Share this article
Share this article
BOSTON, March 5, 2021 /PRNewswire/ ABclonal Biotechnology Co., Ltd., a global life science tools and services provider, acquires Yurogen Biosystems LLC, a contract research organization dedicated to monoclonal antibody discovery using single-B-cell-based SMab
TM platform, to better serve researchers in
in vitro diagnostic, and antibody drug and therapeutic discovery markets worldwide. The acquisition comes after the company announced its $93 million Series C funding and marks the first step as the company expands its footprints from academic research reagents production to
/PRNewswire/ ABclonal Biotechnology, a global life science tools and services provider, recently completed its $92.9 million Series C financing led by.